Recent progress in the treatment of non-systemic juvenile idiopathic arthritis

John M Bridges; Elizabeth D Mellins; Randy Q Cron

doi:10.12703/r/10-23

Recent progress in the treatment of non-systemic juvenile idiopathic arthritis

Fac Rev. 2021 Feb 26:10:23. doi: 10.12703/r/10-23. eCollection 2021.

Authors

John M Bridges¹, Elizabeth D Mellins², Randy Q Cron¹

Affiliations

¹ Children's of Alabama/University of Alabama at Birmingham, Birmingham, Alabama, USA.
² Department of Pediatrics, Program in Immunology, Stanford University, Stanford, California, USA.

Abstract

Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease affecting the joints and other organs that occurs in 1 in 1,000 children in the United States. Given the various categories of JIA, interpretation of the literature can be difficult. In this review, new developments in understanding non-systemic JIA and its treatment will be covered. Recent advances in the journey toward personalized treatment in JIA will be highlighted, including a review of currently available biologic modifiers. Uveitis and the temporomandibular joint will be discussed as particularly challenging treatment issues. Recent guideline updates and literature-guided treatment decisions will be reviewed.

Keywords: DMARD; Juvenile idiopathic arthritis; biologic; temporomandibular joint; uveitis.

Publication types

Review

Grants and funding

The authors declare that no grants were involved in supporting this work.